Impax Asset Management Group plc Has $10.17 Million Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Impax Asset Management Group plc boosted its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 14.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 540,027 shares of the company’s stock after buying an additional 69,424 shares during the quarter. Impax Asset Management Group plc owned approximately 1.17% of Pacira BioSciences worth $10,174,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of PCRX. Pacer Advisors Inc. grew its position in shares of Pacira BioSciences by 129.4% in the third quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock valued at $74,681,000 after purchasing an additional 2,799,434 shares during the last quarter. Assenagon Asset Management S.A. grew its position in shares of Pacira BioSciences by 314.4% in the third quarter. Assenagon Asset Management S.A. now owns 553,114 shares of the company’s stock valued at $8,324,000 after purchasing an additional 419,656 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of Pacira BioSciences by 269.7% in the third quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock valued at $5,955,000 after purchasing an additional 288,662 shares during the last quarter. PDT Partners LLC acquired a new position in shares of Pacira BioSciences in the third quarter valued at approximately $3,469,000. Finally, Empowered Funds LLC acquired a new position in shares of Pacira BioSciences in the third quarter valued at approximately $3,286,000. Institutional investors and hedge funds own 99.73% of the company’s stock.

Analysts Set New Price Targets

PCRX has been the subject of several recent research reports. Royal Bank of Canada reiterated a “sector perform” rating and issued a $18.00 price target on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Needham & Company LLC boosted their price target on Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Barclays cut their price target on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 12th. Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and boosted their price target for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. Finally, HC Wainwright reiterated a “buy” rating and issued a $39.00 price target on shares of Pacira BioSciences in a research note on Wednesday, December 4th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $22.78.

Pacira BioSciences Stock Up 0.4 %

NASDAQ PCRX opened at $25.25 on Tuesday. The business has a fifty day moving average price of $22.60 and a two-hundred day moving average price of $18.29. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $31.67. The stock has a market capitalization of $1.17 billion, a PE ratio of -12.44 and a beta of 0.80.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.